- Disclosure forms provided by the author are available with the full text of this article at NEJM.org.
Gene Therapy Meets Stem Cells
N Engl J Med 2012; 366:567-569 February 9, 2012
Stem cell–based therapies have the potential to repair and even correct the defects related to human diseases. Although tantalizing niche applications have moved forward in the clinical setting, progress seems to be slow, and ethical challenges have yet to be definitively addressed. The goal of developing pluripotent cells that can transmute to organ-specific maturity at our direction, and possibly cure many human diseases, has yet to be attained.
With recent advances, however, gene correction involving stem cells is closer to being within our grasp. Although techniques for correcting genetic abnormalities have been available in the laboratory for years, the tools for manipulating the genome tend to leave traces of unwanted genetic material within the cell or within the genes themselves. Recently, Yusa and colleagues described a tour-de-force study involving the correction of a single gene mutation in induced pluripotent stem cells (iPSCs) derived from patients' own dermal fibroblasts.1 (Since these stem cells are typically derived from a differentiated somatic cell, they differ from embryonic stem cells, which are derived from the early embryo.) Using techniques that appear to leave no residual sequences behind, these investigators replaced a mutated DNA sequence within patient-derived iPSCs with one encoding the normal gene product.
The authors chose to study alpha1-antitrypsin deficiency, which is caused by mutations in SERPINA1, the gene that encodes this serine protease inhibitor (PI). The “normal” variant of this gene (designated PI*M) differs from the most common, severely deficient genotype (PI*Z) by a single base pair, leading to the substitution of a single amino acid (Glu342Lys) in the alpha1-antitrypsin protein. The corrected iPSCs were stimulated to acquire the characteristics of hepatocytes, appropriately including the synthesis and secretion of normal alpha1-antitrypsin. After intrasplenic injection into mice these iPSC-derived, gene-corrected hepatocytes were shown to populate the liver of these mice and to maintain their hepatocyte-like and alpha1-antitrypsin–producing characteristics for many weeks.
Alpha1-antitrypsin deficiency is only one of many monogenic diseases that could be potential targets for this type of corrective approach. Yusa and colleagues go so far as to predict that, should this technology be found to be safe and effective, iPSCs derived from a person could be returned — corrected and hepatocyte-like — to that same person in approximately 4 months (Figure 1Figure 1Ameliorating Alpha1-Antitrypsin Deficiency.). Although it is difficult to achieve the dual goals of safety and efficacy for any new therapeutic agent, the use of genetically manipulated iPSCs as a form of therapy poses unique safety issues, some of which these investigators have addressed. For example, by using native stem cells (derived from a person's own somatic cells), these authors have taken important steps toward addressing concerns about the possible rejection of or reaction to these iPSC-derived hepatocytes.
Stem cells accumulate mutations throughout their genome as they multiply in culture. Some mutations are predictable and well characterized, whereas others appear to occur at random. Of concern is the possibility that an acquired mutation could possess oncogenic properties and lead to neoplasia. The authors offer two observations relative to these concerns: They compared the mutations acquired during growth in culture of both uncorrected iPSCs and gene-corrected iPSCs and found no important differences between the two. They also observed no cancers in the mice that had received the modified iPSCs after 2 weeks. Although these findings are reassuring, they represent only a first step toward documenting the safety of such procedures.
Assuming that the safety of iPSCs will eventually be addressed, we can speculate about the clinical application of patient-specific iPSC therapy in alpha1-antitrypsin deficiency as an illustrative example. Liver failure develops during the first months of life in about 2 to 3% of infants born with this deficiency. Use of corrected iPSCs to prevent disease in infants would probably involve intrauterine treatment or embryonic manipulation before implantation (though it might be easier to select an embryo that lacks the mutation, if one is available). Since this approach comes close to what could be considered embryonal stem cells, it would be safer to focus on instituting treatment later in the life of the affected person. More insidious liver injury, usually manifesting as cirrhosis, can occur at any time in persons with alpha1-antitrypsin deficiency. Destructive lung disease is the other major clinical manifestation of this disorder. It is well accepted that environmental factors increase the risks of lung and liver disease in patients with this disorder and that exposures during childhood are at least as important as exposures later in life. The “corrected iPSC” approach might therefore find its best application early in life, thus raising the stakes in terms of safety, especially with respect to the risk of neoplasia.
Source Information
From National Jewish Health, Denver; and AlphaNet, Miami.
This is a blog that mainly consists of health and public health related articles, research findings from highly recognized journal, journal link, analysis and news update and blogger's experience with patients. all the visitors are most welcome to give feedback. Small effort can make big impact...!
Wednesday, February 15, 2012
Gene Therapy Meets Stem Cells
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment